West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS

West Pharmaceutical Services (NYSE:WST) announced its earnings results on Thursday. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22), Briefing.com reports. The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 18.78%. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.11 earnings per share. West Pharmaceutical Services updated its FY 2024 guidance to 6.350-6.650 EPS.

West Pharmaceutical Services Price Performance

WST stock opened at $284.76 on Friday. West Pharmaceutical Services has a one year low of $265.00 and a one year high of $415.73. The company’s fifty day moving average price is $324.09 and its 200-day moving average price is $355.79. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The company has a market capitalization of $20.74 billion, a PE ratio of 37.57, a price-to-earnings-growth ratio of 6.03 and a beta of 1.00.

Insider Activity at West Pharmaceutical Services

In related news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.